Some illnesses are so rare that there is no financial incentive for pharmaceutical companies to manufacture a drug. The illnesses are ‘orphan diseases’ and their treatment ‘orphan drugs’. In order to encourage their manufacture, governments may offer inducements such as financial benefits before official approval or an extended period of patent protection.